arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MARAVAI LIFESCIENCES HOLDINGS, INC.

MRVI
$7.46 ▲ +0.29 (+4.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

MARAVAI LIFESCIENCES HOLDINGS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1B
Dividend Yield
Revenue Growth 8.5%
Op. Margin -29.3%
ROIC -4.3%
FCF / Share $0.02
Trailing P/E
Price / Book 5.4x
FCF Yield 0.3%
Debt / Equity 0.72
info Valuation on last close. End-of-day price, Sep 22, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.44M
↑ +8.5%
Net Income Profit after all expenses
$-12.42M
↑ +68.6%
Operating Margin Operating profit as % of sales
-29.3%
↓ -794.9% 2th
FCF / Share Free cash flow per share
$0.02
↓ -15.2%
Long-Term Debt Long-term obligations
$147.10M
↓ -39.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
14
Financial Health
26
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 26 quarters